Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Novo Nordisk Strikes Two Antibody Deals
by Ann M. Thayer
December 7, 2015
| A version of this story appeared in
Volume 93, Issue 48
Novo Nordisk is spending $5 million to license Xoma’s XMetA program of allosteric monoclonal antibodies that activate the insulin receptor. Xoma could also receive up to $290 million in milestone payments. Xoma retains rights related to rare diseases, but Novo has an option to license these uses as well. Separately, Novo will pay Ablynx $5.3 million and up to $4.3 million in R&D support over three years to develop Ablynx’s Nanobody line of antibody fragments for an undisclosed disease. Novo has the option to add a second program and pay another $4.3 million. Ablynx could receive milestone payments of up to $194 million per program.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X